Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$8.74 -13.8%	$9.07	$4.88 ▼ $19.58	$189.62M	N/A	121,577 shs	146,968 shs
ACHL Achilles Therapeutics	$1.48	$1.47	$0.63 ▼ $1.51	$60.83M	1.25	592,304 shs	N/A
ATXS Astria Therapeutics	$3.97 +1.8%	$5.09	$3.56 ▼ $12.92	$224.04M	0.45	367,725 shs	878,151 shs
SLRN Acelyrin	$2.05 -1.9%	$2.43	$1.85 ▼ $7.25	$206.86M	1.07	1.21 million shs	1.55 million shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	-13.81%	-17.78%	+14.70%	+873,999,900.00%	+873,999,900.00%
ACHL Achilles Therapeutics	0.00%	0.00%	0.00%	+6.47%	+60.87%
ATXS Astria Therapeutics	+1.79%	-9.38%	-5.92%	-43.45%	-58.17%
SLRN Acelyrin	-1.91%	-15.29%	-5.96%	-0.49%	-56.66%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	2.2861 of 5 stars	3.6	3.0	0.0	0.0	2.5	1.7	0.0
SLRN Acelyrin	2.8902 of 5 stars	3.2	2.0	0.0	0.0	2.7	3.3	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.50	260.41% Upside
ACHL Achilles Therapeutics	0.00	N/A	N/A	N/A
ATXS Astria Therapeutics	3.25	Buy	$30.00	655.67% Upside
SLRN Acelyrin	2.40	Hold	$9.60	368.29% Upside

Current Analyst Ratings Breakdown

Latest ACHL, ATXS, SLRN, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/14/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$47.00 ➝ $47.00
4/29/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	ATXS Astria Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$47.00
4/1/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00
4/1/2025	AARD Aardvark Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$50.00 ➝ $50.00
3/27/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$22.00 ➝ $26.00
3/12/2025	ATXS Astria Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$27.00 ➝ $28.00
3/11/2025	ATXS Astria Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
3/10/2025	AARD Aardvark Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$29.00
3/10/2025	AARD Aardvark Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$22.00
3/10/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$21.00

(Data available from 5/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	$3.49 per share	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	$3.33 per share	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ACHL Achilles Therapeutics	-$69.67M	-$1.65	N/A	N/A	N/A	N/A	-54.45%	-47.68%	N/A
ATXS Astria Therapeutics	-$72.89M	-$1.67	N/A	N/A	N/A	N/A	-43.58%	-29.36%	N/A
SLRN Acelyrin	-$381.64M	-$2.50	N/A	N/A	N/A	N/A	-44.12%	-39.02%	N/A

Latest ACHL, ATXS, SLRN, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q1 2025	SLRN Acelyrin	-$0.95	-$0.55	+$0.40	-$0.55	N/A	N/A
5/13/2025	Q1 2025	ATXS Astria Therapeutics	-$0.48	-$0.58	-$0.10	-$0.58	N/A	N/A
3/19/2025	Q4 2024	SLRN Acelyrin	-$0.86	-$0.79	+$0.07	-$0.79	N/A	N/A
3/11/2025	Q4 2024	ATXS Astria Therapeutics	-$0.45	-$0.44	+$0.01	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
ACHL Achilles Therapeutics	N/A	N/A	N/A	N/A	N/A
ATXS Astria Therapeutics	N/A	N/A	N/A	N/A	N/A
SLRN Acelyrin	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	N/A	N/A
ACHL Achilles Therapeutics	N/A	6.04	6.04
ATXS Astria Therapeutics	N/A	22.38	22.38
SLRN Acelyrin	N/A	7.15	7.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
ACHL Achilles Therapeutics	56.38%
ATXS Astria Therapeutics	98.98%
SLRN Acelyrin	87.31%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
ACHL Achilles Therapeutics	5.38%
ATXS Astria Therapeutics	2.90%
SLRN Acelyrin	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
ACHL Achilles Therapeutics	250	41.10 million	38.89 million	Not Optionable
ATXS Astria Therapeutics	30	56.43 million	54.80 million	Optionable
SLRN Acelyrin	135	100.91 million	86.68 million	Optionable

ACHL, ATXS, SLRN, and AARD Headlines

Recent News About These Companies

ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

May 13 at 1:00 PM | globenewswire.com

Acelyrin (SLRN) Projected to Post Earnings on Tuesday

May 12 at 2:49 AM | americanbankingnews.com

DAFNA Capital Management LLC Sells 514,905 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

May 10, 2025 | marketbeat.com

Acelyrin (SLRN) to Release Quarterly Earnings on Tuesday

May 8, 2025 | marketbeat.com

Alyeska Investment Group L.P. Buys Shares of 1,515,878 Acelyrin, Inc. (NASDAQ:SLRN)

May 8, 2025 | marketbeat.com

Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote “FOR” the Proposed Transaction with Alumis

May 6, 2025 | globenewswire.com

Susquehanna Fundamental Investments LLC Takes $746,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

May 5, 2025 | marketbeat.com

Almitas Capital LLC Raises Stake in Acelyrin, Inc. (NASDAQ:SLRN)

May 4, 2025 | marketbeat.com

Acelyrin urges stockholders to vote for proposed merger with Alumis

May 2, 2025 | finance.yahoo.com

ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis

May 1, 2025 | globenewswire.com

T. Rowe Price Investment Management Inc. Boosts Stock Position in Acelyrin, Inc. (NASDAQ:SLRN)

April 29, 2025 | marketbeat.com

Bank of Montreal Can Cuts Stock Holdings in Acelyrin, Inc. (NASDAQ:SLRN)

April 28, 2025 | marketbeat.com

JPMorgan Chase & Co. Sells 232,534 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

April 27, 2025 | marketbeat.com

Acelyrin, Inc. (NASDAQ:SLRN) Short Interest Update

April 21, 2025 | marketbeat.com

Alumis and ACELYRIN Announce Amended Merger Agreement

April 21, 2025 | globenewswire.com

ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN

April 16, 2025 | businesswire.com

Wellington Management Group LLP Buys New Shares in Acelyrin, Inc. (NASDAQ:SLRN)

April 16, 2025 | marketbeat.com

ExodusPoint Capital Management LP Takes $423,000 Position in Acelyrin, Inc. (NASDAQ:SLRN)

April 15, 2025 | marketbeat.com

Alumis Inc.; ACELYRIN, INC.: Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

Alumis Inc. and ACELYRIN, INC. File Joint Definitive Proxy Statement for Proposed Merger

April 5, 2025 | finanznachrichten.de

STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating The Merger - SLRN, TURN, BHLB, MHLD

March 30, 2025 | morningstar.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACHL, ATXS, SLRN, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$8.74 -1.40 (-13.81%)

As of 05/14/2025 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Achilles Therapeutics NASDAQ:ACHL

$1.48 0.00 (0.00%)

As of 03/26/2025

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient. It also develops CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

Astria Therapeutics NASDAQ:ATXS

$3.97 +0.07 (+1.79%)

As of 05/14/2025 04:00 PM Eastern

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.

Acelyrin NASDAQ:SLRN

$2.05 -0.04 (-1.91%)

As of 05/14/2025 04:00 PM Eastern

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time